发明名称 Hepatitis C Virus Inhibitors
摘要 The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
申请公布号 US2015322048(A1) 申请公布日期 2015.11.12
申请号 US201514807084 申请日期 2015.07.23
申请人 BRISTOL-MYERS SQUIBB COMPANY 发明人 Lavoie Rico;Bender John A.;Yang Zhong;Belema Makonen;Lopez Omar D.;Chen Qi;Wang Gan;Hewawasam Piyasena
分类号 C07D403/14;A61K45/06;A61K31/4178;A61K31/4545;C07D471/04;A61K31/437;C07D487/04;A61K31/4985;C07D405/14;C07D401/14;A61K31/4709;A61K31/498;A61K31/4375;C07D413/14;A61K31/5377;A61K31/4184 主分类号 C07D403/14
代理机构 代理人
主权项 1. A compound of Formula (I)or a pharmaceutically acceptable salt thereof, wherein: X and X′ are each independently selected from CH, CR1, and N; Y and Y′ are each independently selected from CH, CR2, and N; provided that no more than two of X, X′, Y, and Y′ are N; R1 and R2 are independently selected from each R3 is independently selected from hydrogen, cyano, and halo; each R4 is independently selected from hydrogen, and alkyl, wherein the alkyl can optionally form a fused three- to five-membered ring with an adjacent carbon atom wherein said ring is optionally substituted with one or two methyl groups; or, R4 and the carbon to which it is attached form an ethylene group; each R5 is independently selected from hydrogen and —C(O)R6; each R6 is independently selected from alkoxy, alkyl, arylalkoxy, arylalkyl, cycloalkyl, heterocyclyl, heterocyclylalkyl, (NRcRd)alkenyl, and (NRcRd)alkyl; and each R7 and R8 is independently selected from hydrogen and alkyl.
地址 Princeton NJ US